Here’s why Citi says crypto prices have been weak recently
LONDON - EKF Diagnostics Holdings plc (AIM:EKF), a global diagnostics business, has repurchased 309,384 of its ordinary shares at a price of 26.6 pence per share, according to a company statement released Monday.
The shares purchased in the buyback on October 31 will be held in treasury. The transaction was executed in two blocks, with 218,384 shares purchased at 11:31 and 91,000 shares at 15:03, both on the AIM exchange.
Following the buyback, EKF’s total issued share capital consists of 449,093,790 ordinary shares, with 7,330,636 shares held in treasury. This leaves 441,763,154 ordinary shares carrying voting rights.
As part of the transaction, EKF acquired 91,000 shares from Harwood, acting as investment manager to Oryx International Growth Fund Limited and North Atlantic Smaller Companies Investment Trust PLC. The company purchased 30,333 shares from Oryx and 60,667 from NASCIT.
The company noted that Harwood facilitated this transaction to ensure that the aggregate indirect beneficial interest of Christopher Mills, a Non-Executive Director, remains at approximately the same level and does not exceed 30% of the company’s total voting rights. Following the transaction, Mills’ aggregate indirect interest in the company stands at 130,269,000 ordinary shares.
EKF Diagnostics is an AIM-listed business focused on point-of-care analyzers in hematology and diabetes, as well as life sciences services providing enzymes and custom products for diagnostic, food, and industrial applications. The company operates five manufacturing sites across the US and Germany and sells into over 120 countries worldwide.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.